Treatment of
osteoporosis commonly involves drugs that inhibit bone resorption.
These include bisphosphonates, estrogens, selective estrogen
receptor modulators (SERMS) and calcitonin.
Osteomark NTx can measure response to treatment in as little as
3-6 months after starting therapy.
Mean change in NTx/Cr as % of
baseline for patients taking Alendronate or Placebo.
Patient monitoring of those on therapy has been shown to
increase adherence by 57% compared with no monitoring. Patients
with good marker response to raloxifene therapy were 92% more
likely to adhere to therapy compared with usual care.
Therapy monitoring allows the physician to be confident of
patient compliance.